<DOC>
	<DOCNO>NCT01898312</DOCNO>
	<brief_summary>Ovarian steroid , well synthetic counterpart gestagens estrogen role breast cell proliferation development breast cancer . Here , effect progesterone receptor modulator , mifepristone , cell proliferation human breast tissue vivo study woman BRCA-1 -2 mutation . Our preliminary result implicate possible protective effect mifepristone breast epithelium . The ability mifepristone block breast epithelial cell proliferation may prevent tumorigenesis may also prove beneficial use contraceptive purpose indication . The propose project concern Randomized Controlled Trial mifepristone versus placebo treatment woman BRCA-1or -2 mutation high risk/incidence breast cancer ovarian cancer .</brief_summary>
	<brief_title>BRCA1/2 Effect Mifepristone Breast</brief_title>
	<detailed_description>Objectives • Research objective To study safety effect treatment mifepristone , progesterone receptor modulator , epithelial cell proliferation human breast tissue woman BRCA-1 -2 mutation prior protective mastectomy . Project description • Hypothesis/ Theory Mifepristone treatment exerts antiproliferative , protective effect breast tissue woman BRCA-1 -2 mutation Study Design Randomized , double blind , placebo control trial . Women recruit among patient BRCA-1 -2 mutation schedule prophylactic mastectomy . Included woman randomize 3-month treatment mifepristone , 50 mg ( Mifegyne , Exelgyn , Paris , France ) placebo take orally every second day . Breast biopsy obtain luteal phase prior start treatment surgery .</detailed_description>
	<mesh_term>Disease Susceptibility</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>Inclusion criterion : Premenopausal woman , &gt; /= 18 year age good general health regular menstrual cycle ( 2535 day ) willing able participate give informed consent . woman BRCA1/2 mutation decide undergo risk reduce mastectomy Exclusion criterion include : Any hormonal treatment use within 2 month prior study start Any contraindication mifepristone</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>